選択された言語で薬の詳細が利用できない場合は、元のテキストが表示されます

Indium (in111) oxinate

OB_Indium Oxinate_147226-PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Tin containing radioactive kit (radiolabel in lead shielding and buffer)


1. NAME OF THE MEDICINAL PRODUCT

Indium (In111) Oxinate
37 MBq/mL; Radiopharmaceutical precursor.

Indium (In-111) chloride

DRN 4908 (= Code on vial)

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Indium (In111) Oxinate: Indium (In-111) chloride 37 MBq/mL at [YYYY-MM-DD hh:mm] h CET, Oxine
0.025 mg
Tris: Tris buffer 0.2 M, pH 8.
3. LIST OF EXCIPIENTS

Indium (In111) Oxinate: Sodium acetate trihydrate, acetic acid anhydrous, ferric chloride hexahydrate,
sodium chloride, hydrochloric acid and water for injections.
Tris: Hydrochloric acid, trometamol and water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

The tin contains two vials:
Indium (In111) Oxinate: Radiopharmaceutical precursor. 37 MBq/1 mL
Tris: Solution for injection. 3 mL

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use after in-vitro labelling of blood cells.
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND
REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

First use: [YYYY-MM-DD hh:mm] h CET

OB_Indium Oxinate_147226-8. EXPIRY DATE

EXP: [YYYY-MM-DD hh:mm] h CET

9. SPECIAL STORAGE CONDITIONS

Store below 25 °C.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Radioactive waste disposal should be in accordance with national regulations. After decay of
radioactivity there are no special precautions for waste disposal.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Curium Netherlands B.V., Westerduinweg 3, 1755 LE Petten, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

88/381/93-C

13. BATCH NUMBER

Lot: [12345]

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE



16. INFORMATION IN BRAILLE

Justification for not including Braille accepted

OB_Indium Oxinate_147226-PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING

Lead shielding In-111 oxinate


1. NAME OF THE MEDICINAL PRODUCT

Indium (In111) Oxinate
37 MBq/mL; Radiopharmaceutical precursor.

Indium (In-111) chloride

DRN 4908 (= Code on vial)

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Indium (In-111) chloride 37 MBq/mL at [YYYY-MM-DD hh:mm] h CET, Oxine 0.025 mg

3. LIST OF EXCIPIENTS

Sodium acetate trihydrate, acetic acid anhydrous, ferric chloride hexahydrate, sodium chloride,
hydrochloric acid and water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Radiopharmaceutical precursor. 37 MBq/1 mL

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use after in-vitro labelling of blood cells.
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND
REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

First use: [YYYY-MM-DD hh:mm] h CET

8. EXPIRY DATE

EXP: [YYYY-MM-DD hh:mm] h CET
OB_Indium Oxinate_147226-9. SPECIAL STORAGE CONDITIONS

Store below 25 °C.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Radioactive waste disposal should be in accordance with national regulations. After decay of
radioactivity there are no special precautions for waste disposal.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Curium Netherlands B.V., Westerduinweg 3, 1755 LE Petten, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

88/381/93-C

13. BATCH NUMBER

Lot [12345]

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE



16. INFORMATION IN BRAILLE

Justification for not including Braille accepted

OB_Indium Oxinate_147226-MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
In case of radiopharmaceuticals the vial should be labelled in accordance to the article 66(3) of
Directive 2001/83.

Vial label: In-

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

DRN 4908 In-
2. METHOD OF ADMINISTRATION


3. EXPIRY DATE

EXP: [YYYY-MM-DD hh:mm] h CET

4. BATCH NUMBER

Lot: [00000/000]

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

37 MBq/1 mL
[YYYY-MM-DD hh:mm] h CET

6. OTHER

Curium Netherlands B.V.



OB_Indium Oxinate_147226-MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Vial label: Tris buffer


1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Tris buffer 0.2 M pH 8.Solution for injection

2. METHOD OF ADMINISTRATION

For intravenous use after in-vitro labelling of blood cells.

3. EXPIRY DATE

EXP [YYYY-MM-DD]


4. BATCH NUMBER

Lot [000000]

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

mL

6. OTHER





Indium (in111) oxinate

薬局からのオファーでの商品の選択
 
在庫あり | 配送先 79 CZK
1 790 CZK
 
在庫あり | 配送先 79 CZK
199 CZK
 
在庫あり | 配送先 79 CZK
609 CZK
 
在庫あり | 配送先 79 CZK
135 CZK
 
在庫あり | 配送先 79 CZK
609 CZK
 
在庫あり | 配送先 79 CZK
499 CZK
 
在庫あり | 配送先 79 CZK
435 CZK
 
在庫あり | 配送先 79 CZK
15 CZK
 
在庫あり | 配送先 79 CZK
309 CZK
 
在庫あり | 配送先 79 CZK
155 CZK
 
在庫あり | 配送先 79 CZK
39 CZK
 
在庫あり | 配送先 79 CZK
99 CZK
 
在庫あり | 配送先 79 CZK
145 CZK
 
在庫あり | 配送先 79 CZK
85 CZK

プロジェクトについて

相互作用のレベル、副作用、薬価とその選択肢のレベルでの麻薬比較を目的とした自由に入手可能な非営利プロジェクト

詳細情報